Wall Street analyst estimates for Cingulate Inc. (CING): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
Valuation Ratios
| Price / Book | 1.13 |
| EV / EBITDA | -1.10 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $178912 | $842353 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$178912 | -$842353 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $9.1M | $5.1M | $8.4M | $9.0M | $15.5M | $9.4M | $9.8M |
| Selling, General & Admin | $2.4M | $1.1M | $12.3M | $8.5M | $7.3M | $6.2M | $10.2M |
| Operating Expenses | $11.5M | $6.2M | $20.7M | $17.5M | $22.8M | $15.6M | $19.9M |
| Operating Income | -$11.6M | -$7.1M | -$20.7M | -$17.5M | -$22.8M | -$15.6M | -$19.9M |
| EBITDA | -$11.5M | -$6.2M | -$20.0M | -$17.1M | -$22.2M | -$15.0M | -$19.4M |
| Interest Expense | 0 | $54605 | $33407 | $174000 | 0 | 0 | $924446 |
| Pre-tax Income | -$11.5M | -$7.2M | -$20.7M | -$17.7M | -$23.5M | -$16.6M | -$22.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$11.5M | -$7.2M | -$20.7M | -$17.7M | -$23.5M | -$16.6M | -$22.4M |
| EPS | $-242.89 | $-12.70 | $-55.80 | $-31.20 | $-311.99 | $-10.20 | $-4.13 |
| EPS (Diluted) | $-242.89 | $-12.70 | $-55.80 | $-31.20 | $-311.99 | $-10.20 | $-4.13 |
| Shares Outstanding (Diluted) | $1.4M | $1.4M | $1.4M | $1.4M | $2.3M | $3.8M | $5.4M |
Price
| Price | $5.09 |
| Market Cap | $69M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLR · BCTX · CASI · CLSD · ENTO · KAPA · LEXX
Explore sector: Healthcare · Biotechnology
More sections of CING: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks